• News

    Precision For Medicine Taps Mairead Kehoe as Executive Vice President, Clinical Solutions

    VETERAN STRATEGIST AND LEADER TO GUIDE THE CONTINUED EXPANSION AND GROWTH
    OF PRECISION’S INDUSTRY-LEADING GLOBAL CLINICAL TRIALS SOLUTIONS

     

    January 27, 2020– New York, NY – Precision for Medicine, the first comprehensive, fully-integrated biomarker-driven clinical research services organization, today announced that veteran healthcare leader Mairead Kehoe has been named its new Executive Vice President, responsible for overseeing its global clinical solutions delivery.

    In adding Ms. Kehoe’s expertise and leadership, Precision builds upon its novel, biomarker-driven approach— integrating translational sciences and clinical trials— and strengthens its industry-leading position as experts in early development and late-phase trials for innovative  life changing therapies. Precision’s growing global footprint now includes 34 offices worldwide with nearly 2000 employees, and is managing trals in over 35 countries.

    Ms. Kehoe joins Precision with 25+ years of industry experience from biotech, CRO and biopharma clinical research industry, spanning all aspects of global clinical development. Her experience includes management and leadership positions focused on the strategic planning and quality conduct of global clinical programs encompassing end-to-end drug development operations, from early development through to product approval – seeing first-hand the positive impact of quality and thoughtful clinical development.

    Most recently, Ms. Kehoe held the position of Corporate Vice President of Global Clinical Quality Assurance (GCP) & Data Sharing/Disclosure at Celgene Corp. where she was responsible for the global leadership of the GCP programs for Early Development, R&D and Medical Affairs. Prior to this, Mairead held the position of Vice President, Global Clinical Operations and was responsible for the strategic planning, oversight and leadership for the global Clinical Operations functions at Celgene.  Prior to joining Celgene, Ms. Kehoe was the Executive Director, Global Clinical Operations for i3/Ingenix and was responsible for the strategic and operational leadership across core therapeutic areas. 

    Guiding the delivery of Precision’s global clinical solutions, Ms. Kehoe will continue to evolve Precision’s integrated team approach, utilizing clinical science, exceptional data integrity and quality operations to facilitate timely and targeted endpoint-driven decision making– providing clients with a unique, end-to-end operating platform.

    Discussing Ms. Kehoe’s unique experience and qualifications, Pat Devitt, President, Precision for Medicine, Clinical Solutions adds, “We are extremely fortunate to be adding a veteran leader such as Mairead to drive the growth and expansion of our global clinical solutions offering— expertly guiding us in our growth strategy as well as in the proactive planning and quality execution of programs and cross-organizational processes.”

    Expressing her enthusiasm for the opportunity, Ms. Kehoe explains, “I am very excited to be part of the Precision for Medicine Team. It is rewarding to work alongside such a group of highly experienced and passionate professionals focused on quality drug development, with the common goal of bringing forward meaningful treatment options for patients and their families dealing with challenging diseases.”

    About Precision for Medicine,
    Precision for Medicine, part of Precision Medicine Group, is the first comprehensive, fully integrated CRO devoted to oncology and rare disease innovation. With over 1900 experts in 34 offices worldwide, Precision offers novel clinical trial designs, industry-leading operational and medical experts, and advanced biomarker solutions for pharma and biotech innovators. For more information, please visit: https://www.precisionmedicinegrp.com/pfmord/.


    Media Contact:

    Louis Landon
    Precision Medicine Group Media Relations
    310-984-7707
    louis.landon@precisionformedicine.com

  • Thought Leadership

    Data-Driven Clinical Planning: Building Value-Added Data Assets

    The increasing availability of public data sets offers a transformational opportunity for insight-driven planning at all phases of the drug development life cycle. Yet too often organizations adopt an ad hoc approach to data analysis rather than build data assets for both immediate and future use.

  • News

    Precision for Medicine Significantly Expands Berlin Lab as Demand For Immune Monitoring Continues to Grow

    NEW STATE-OF-THE-ART FACILITY DRAMATICALLY INCREASES CAPACITY FOR CLINICAL TRIALS AND OFFERS CLIENTS FIRST-OF-ITS-KIND CELL PROFILING CAPABILITIES COMBINING EPIGENETICS AND FLOW CYTOMETRY

     

    BERLIN, GERMANY – 27 NOVEMBER 2019 – Precision for Medicine, part of Precision Medicine Group, today announced that they have opened a new 1,600 m2 Berlin-based laboratory, for the first time combining its proprietary Epiontis ID™ epigenetic immune-monitoring technology with advanced flow cytometry capabilities, along with a full-service biorepository and cell processing laboratory. Focusing on the rapidly growing immuno-oncology and neuroimmunology markets, the new lab creates a 10-fold increase in Precision’s European capacity. In addition, the new dedicated facility boosts Precision’s full-time European workforce to well over 300 employees and bolsters its expanding clinical trials footprint that now includes offices in Edinburgh, Paris, Geneva, Budapest, Bucharest, Bratislava, and Belgrade and additional staff throughout Europe and the United Kingdom.

  • Events

    Companion Diagnostic Expert Presenting at IVD Clinical & Regulatory Affairs Conference [Dec 12-13]

     

    Precision will be attending at the upcoming IVD Clinical & Regulatory Affairs Conference. Our companion diagnostic expert, Karen Richards, will be there hosting a panel and presenting a case study that you don’t want to miss.

    Thursday, December 12 | 4:30 PM Panel Discussion
    Notified Body Fireside Chat: Perspective on Certification & Progress on Designation 

    Friday, December 13 | 9:15 AM Case Study Presentation
    Top 4 Considerations for Development and Implementation of a Companion Diagnostic

    Contact us at info@precisionformedicine.com to set-up time to meet Karen in San Diego or to learn more about our diagnostic capabilities.

  • News

    PRECISION FOR MEDICINE AND AKOYA PARTNER TO DEVELOP ADVANCED LIQUID BIOPSY AND TISSUE BIOMARKER TESTS

    MENLO PARK, CA and HOUSTON, November 5, 2019 – Akoya Biosciences, The Spatial Biology Company™ today announced a strategic alliance with Precision for Medicine (formerly ApoCell), a pioneer in customized biomarker solutions, to develop proprietary liquid biopsy and tissue biomarker tests using Akoya’s Vectra® Polaris™ System. By combining the Vectra Polaris system with Precision for Medicine’s ApoStream® technology, the collaboration is designed to advance immuno-oncology candidates in clinical trials using both tumor biopsies and liquid biopsies to generate data required for assessing drug efficacy and validation of companion diagnostics (CDx).

    “We are very excited to be the first commercial laboratory to launch the Vectra Polaris system for image analysis of circulating tumor cells following ApoStream’s isolation and enrichment functionality,” said Darren Davis, PhD, Precision for Medicine Senior Vice President. “Together, these technologies will enable accelerated drug development through detection of biomarkers in liquid biopsies. These tools have enabled our scientists to better understand the biological correlation of circulating metastatic cancer cells with cancer cells present in the tumor tissue.”

    Circulating tumor cells (CTCs) have long been known to exist in cancer patients’ blood. However, the promise of clinical application of CTCs as a liquid biopsy has not born fruit because these cells are difficult to detect using current molecular biology techniques. Precision for Medicine’s proprietary ApoStream technology captures significant quantities of rare circulating cancer cells from whole blood for characterization using Akoya’s Opal™ technology and Vectra Polaris imaging platform. ApoStream has been used in more than 80 clinical trials, including several ongoing phase III studies for CDx development.

    Akoya’s Vectra Polaris Automated Quantitative Pathology System, part of the company’s Phenoptics 2.0 next-generation biomarker multiplexing platform, enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches. The Vectra Polaris system integrates high throughput, seven-color multispectral imaging with whole-slide scanning in a simplified digital pathology workflow to support the quantification and analysis of tissue sections discernible with Opal detection kits. A recent meta-analysis of several studies showed that incorporating spatial information using Akoya’s multiplexed immunofluorescence technology is important for improving the predictive accuracy of immuno-oncology biomarkers.

    The Phenoptics™ portfolio is capable of interrogating multiple protein markers on any tissue or cytology slide preparation. Precision for Medicine has validated several immune biomarker panels across various therapeutic applications using both types of preparation. These immune panels are currently being used to monitor immune cell infiltration including cancer, psoriasis, lupus and atomic dermatitis.

    “The Vectra Polaris imaging system offers an innovative approach to assessing immunotherapy candidates in translational and clinical research,” said Dr. Cliff Hoyt, Akoya Vice President of Translational and Scientific Affairs. “We are pleased to see this technology paired with ApoStream for a comprehensive method of imaging CTCs and improving our understanding of disease mechanisms in cancer.”

    For more information on ApoCell and the ApoStream technology, please click here.

     

    About Precision for Medicine

    Precision for Medicine is the first biomarker-driven clinical research services organization supporting  life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with more than 1,900 employees in 34 locations in the US, Canada, and Europe. For more information, visit www.PrecisionForMedicine.com.

     

    About Akoya

    Akoya Biosciences, The Spatial Biology Company™, offers the most comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has two industry-leading platforms that empower investigators and researchers to gain a deeper understanding of complex diseases such as cancer, and other immune system or neurological disorders. The CODEX® system is the only benchtop platform that can efficiently quantify more than 40 biomarkers and is ideally suited for biomarker discovery. The Phenoptics™ platform is the only end-to-end multiplexed immunofluorescence solution with the robustness and high throughput necessary for translational research and clinical trials. For more information, please visit https://www.akoyabio.com/.   

     

    Media Contact – Precision for Medicine
    Louis Landon, Precision Medicine Group Media Relations
    310-984-7707
    louis.landon@precisionformedicine.com

     

    Media Contact – Akoya
    Michelle Linn, Bioscribe, Inc.
    774-696-3803
    michelle@bioscribe.com

  • Thought Leadership

    Delivering on the Promise of Precision Medicine: The Critical Role of Specialty Labs

    The promise of precision medicine is the delivery of the right treatment to the right patient at the right time. Increasingly, oncologists are formulating cancer treatment plans based on insights from complex laboratory and imaging tests that characterize an individual patient’s tumor at a molecular level. However… 

  • Events

    QuartzBio presenting at D4 Europe

     

    Don’t miss QuartzBio at the upcoming D4 Europe Summit in Switzerland, where Matthew Hall will discuss the tools and strategies industry leaders leverage to turn their data chaos into a data asset for insight generation.

  • Thought Leadership

    Four key steps to develop an oncology CDx

    In this article published in Regulatory Focus, Precision for Medicine IVD and CDx experts discuss how to effectively plan for successful CDx development.

    Read the full article here.

  • Thought Leadership

    Optimizing Gene Therapy Development

    Development of a gene therapy is a complicated undertaking, fraught with technical challenges and regulatory complexities. However, as gene therapy development advances with better technology and increased FDA regulatory guidance, there is great promise for this therapeutic area to yield clinical benefit.

  • News

    Precision for Medicine Receives CIR (French Research Tax Credit) Accreditation

    PARIS, FRANCE –  06 August 2019 — Precision for Medicine, the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively, today announced that it has received CIR accreditation for a three-year period from the French Ministry of Higher Education and Research.

    The French R&D tax credit initiative (‘Crédit d’Impôt Recherche’, CIR) gives eligible research-based French companies, who are subject to corporate tax in France, the ability to claim tax relief on costs generated in R&D activities outsourced to Precision for Medicine.

    Under this accreditation, the French Ministry of Higher Education and Research has also recognized Precision for Medicine’s UK and Spanish affiliates as reputable cross-border R&D experts.

    Andrea Cotton-Berry, Precision for Medicine’s Global Head of Strategic Development, commented: “We are thrilled to receive this accreditation as it allows our current and future clients in France to benefit from a tax relief of up to 30% of their R&D expenditure committed to Precision for Medicine.” 

     

    About Precision for Medicine
    Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with nearly 2,000 employees in 34 locations in the US, Canada, and Europe. For more information, visit precisionformedicine.com.

     

    # # #

     

    Media Contact:
    Louis Landon, Precision Medicine Group Media Relations
    310-984-7707
    louis.landon@precisionformedicine.com

  • News

    Precision for Medicine launches biospecimen solutions offering with acquisition of ProMedDx and GLAS

    ADDITION OF LEADING SUPPLIERS BOLSTERS PRECISION’S BIOMARKER SERVICE OFFERINGS– BRINGING UNPARALLELED SCIENCE, SCALE, AND SERVICE TO THE BIOSPECIMEN INDUSTRY

    BETHESDA, MD – August 1, 2019 – Precision for Medicine, part of Precision Medicine Group, announced it has acquired leading biospecimen providers ProMedDx and GLAS, significantly expanding its capabilities and expertise in the biospecimen solutions space. With the acquisitions, Precision now offers an unmatched level of scientific understanding, high-quality specimen solutions, and global scale. 

    The addition of ProMedDx and GLAS establishes an unrivaled biospecimen solutions platform within Precision, which operates one of the largest biorepositories in the world. ProMedDx is known throughout the diagnostics industry for its high-quality biofluid specimens, while GLAS is a leader in tissue-based samples. With an expanded sourcing network and client base, along with an enhanced global laboratory infrastructure, Precision can effectively leverage its unique insight as a scientific solutions provider to supply clients with hand-selected, fit-for-purposes specimens for R&D, biomarker development, and companion diagnostics.

    Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Combining two world-class biospecimen organizations, across all specimen types, Precision further enhances its abilities to enable life science innovators with scientifically robust services to accelerate the pace of discovery, development, and commercialization of biomarkers.

    ProMedDx is led by founders Jim Boushell and Jim Sperzel; GLAS is led by founder and pathologist Cullen Taylor, MD.

    Commenting on the significance of the acquisitions, Precision for Medicine president Chad Clark explains, “We believe in the power of biomarkers to lead to novel, life-changing therapies, and we remain dedicated to providing unmatched, scientifically grounded global services. By bringing ProMedDx and GLAS into the Precision family, we are proud to offer unparalleled, global biospecimens solutions while also expanding our footprint in the exploding Massachusetts and North Carolina biotechnology sectors.”

    In describing Precision’s unique capabilities, ProMedDx co-founder Jim Boushell comments, “Precision’s reputation as an expert in biomarker sciences is a real differentiator. Having been in the specimen industry for over 20 years, I can attest there are no other companies that possess Precision’s level of scientific understanding or breadth of solutions. We are thrilled to be joining Precision and leveraging its translational and scientific expertise to deliver the highest-quality solutions to the biopharmaceutical and diagnostic industry.”

    Cullen Taylor, MD of GLAS adds, ”Clearly, the life sciences industry relies heavily upon medical and scientific insight. However, this expertise is often in short supply in biospecimen provision. It’s why we founded GLAS. By teaming up with Precision, we are able to expand this on-the-ground medical expertise to a highly advanced and expansive lab and clinical network—a hugely important distinction in the biospecimen industry.”

    About Precision for Medicine
    Precision for Medicine supports life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research that take advantage of the latest advancements in science and technology, focusing predominantly on genomics, immune-response assays, global specimen logistics, biomarker analytics, companion diagnostics, and clinical trial execution. Precision for Medicine is part of Precision Medicine Group, with nearly 2,000 employees in 34 locations in the US, Canada, and Europe. For more information, visit precisionformedicine.com. For more information about our biospecimen solutions, visit precisionbiospecimens.com.

     

    # # #

    Media Contact:
    Louis Landon, Precision Medicine Group Media Relations
    310-984-7707
    louis.landon@precisionmedicinegrp.com

  • News

    QuartzBio™, part of Precision for Medicine, Expands Computational Biology and Launches Boston Office

    NEW BOSTON TEAM PROVIDES BIOTECH CLIENTS WITH MULTIOMIC BIOMARKERS, CHARACTERIZATION OF DISEASE BIOLOGY, AND MECHANISM OF ACTION ANALYSIS

    JULY 16, 2019 – BOSTON, MAQuartzBio™, part of Precision for Medicine, today announced a significant expansion of its computational biology and multiomic data integration capabilities through the launch of a Boston-based office. The new office is one of many recent investments in Artificial Intelligence and computational biology expertise to cement its position as a leading solution for the integration, and analysis of biological data to support biomarker-guided drug development.

    QuartzBio is accelerating its knowledge management, systems biology and mechanism-driven analytic capabilities to improve drug developers’ and translational researchers’ ability to make connections within the multiomic data ecosystems of drug discovery and development. With these expanded capabilities, QuartzBio will be able to better inform pre-clinical disease modeling and target pathway selection as well as response prediction and mechanism of action characterization. At present, the QuartzBio team has worked successfully with biomarker data from over 100 clinical trials and prior knowledge data sets.

    In establishing the new office, QuartzBio welcomes industry leader Dr. Renee Deehan-Kenney as Vice President of Computational Biology, whose responsibility includes growing the existing QuartzBio presence in Boston as well leading a global computational biology and translational informatics team.

    Prior to QuartzBio, Dr. Deehan-Kenney served as Vice President of Biology and Bioinformatics at PatientsLikeMe, where she built a multi-disciplinary team responsible for managing and analyzing the intersection of multi-omics measurements together with patient-generated health data.   She was also principal investigator of the DigitalMe program aimed to digitize an individual’s health through the capture and analysis of multi-modal health measurements. Previously, Dr. Deehan-Kenney served as Chief Scientific Officer of  SelventaÔ, a systems biology platform company that analyzed rich omics data from pre-clinical and clinical trials for partners in pharma, biotech and consumer products.  At Selventa, Dr. Deehan-Kenney led dozens  of commercial biomarker and disease modeling engagements and managed the scientific delivery team responsible for development of new computational approaches that maximized the insights gained from RNA expression and other -omics measurements. 

    Commenting on the additions to the QuartzBio team, QuartzBio’s Scott Marshall, managing director, explains, “across the industry, we have seen the impact of biomarker data when used in real-time and cross-trial. Dr. Deehan-Kenney and our new Boston team bring a unique expertise in systems and computational biology,  and we are excited to be able to offer innovators a best-in-class solution for data integration and bioinformatics analysis, as well as better support our growing client base in Boston.”

    Adding her enthusiasm, Dr. Deehan-Kenney elaborates: “I’m proud to join such a talented team of scientists at QuartzBio and am impressed by the platform they have built to manage and analyze complex biomarker data from clinical trials.  I’m looking forward to collaborating with the team to expand both data-driven and mechanistic modeling approaches that characterize the unique biology of patients and pre-clinical models to ensure that they receive the most safe and effective treatments in a timely manner.”


    About Precision for Medicine
    Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies novel biomarker approaches to clinical research leveraging the latest advancements in science and technology. Precision for Medicine is part of Precision Medicine Group, with over 1,900 employees in 34 locations in the US, Canada, and Europe. For more information, please visit: www.precisionformedicine.com.

    About QuartzBioTM
    QuartzBio is a technology driven multiomic data integration and informatics solution.  It combines the first platform to successfully integrate diverse biomarker data with AI and computational biology based approaches for insight generation — making the complex connections within clinical data ecosystems a reality.For more information, please visit: www.quartzbio.com

                                        # # #

    Media Contact
    Louis Landon, Precision Medicine Group Media Relations

    310-984-7707
    louis.landon@precisionmedicinegrp.com

  • News

    Precision for Medicine to Provide Real-Time Laboratory Testing Services in Unique Lymphoma Patient Stratification Study

    HOUSTON, TX – May 14, 2019 — Precision for Medicine, a Precision Medicine Group company, announced that it will provide its state-of-the-art laboratory services to perform drug assessment as part of a new personalized clinical trial designed to identify the most effective therapies for individual lymphoma patients at The University of Texas MD Anderson Cancer Center.

  • News

    Getting Personal with Precision Medicine

    The definition of personalized medicine has expanded beyond tailored medical treatment to encompass drug development, care delivery and consumer engagement—while precision medicine refers to the tailoring of medical treatment to the characteristics of a patient subpopulation. This PharmaVoice cover story explores the distinctions, the challenges and the implications, including insights from Precision for Medicine’s own Chad Clark.  

    Read the article

  • News

    Challenges of Developing Precision Medicine

    From continually evolving science to outdated business models, precision medicine faces hurdles that challenge its promise. PharmaVoice interviews industry leaders, including Precision for Medicine President Chad Clark, on the issues they encounter—and the solutions they foresee.  

    Read the article

  • Thought Leadership

    To Flow or Not to Flow: Immune Cell Profiling in Translational Research

    Immune cell profiling is becoming an increasingly indispensable part of the drug development process. Insights gained from profiling of the immune system can be used to optimize therapeutic design and treatment strategies. In this brief, Precision for Medicine experts share their expertise and address the pros and cons of Flow Cytometry and Epigenetic Immune Monitoring.

    Download the white paper today.

  • Thought Leadership

    The success of gene therapy depends on…diagnostic testing

    In this Knect365 article, David Parker, PhD, Precision’s Senior VP, Diagnostics Solutions, explains why diagnostic tests are of critical importance to both the commercial and therapeutic success of gene therapies—then shares developer’s strategies to combat the reimbursement issues that are creating serious access challenges for such tests. 

    Read the article

  • News

    2020: What does the future hold for the manufacturing and clinical landscape?

    What does the future hold for the manufacturing and clinical landscape? Pharma iQ asked Precision leaders Scott Marshall, PhD and Jeremy Schafer, PharmD, MBA. From gene therapy cures for chronic diseases to continuing price pressure on manufacturers, the role of machine learning to the role of companion diagnostics, their insights point the way to major developments in 2019.

     

    To read the full article, click here

  • Thought Leadership

    Using Selection Biomarkers and Unraveling the Resulting Data to Drive Clinical Trial Success

     

    Biomarkers can deliver powerful advantages to clinical trials—if they are used correctly. Chad Clark, President, Precision for Medicine; Scott Marshall, Managing Director, Translational Informatics and Diagnostic Services, Precision for Medicine; and Cliff Culver, Senior Vice President, Precision Medicine Group, share their insights in this article for the Journal of Clinical Trials.

  • Articles , News

    Precision for Medicine Acquires Industry-leading Artificial Intelligence Technology, Significantly Expands Cloud-based Multiomic Data Integration and Informatics Platform QuartzBio™

    ADDITION OF NATIVE ARTIFICIAL INTELLIGENCE CAPABILITY PROVIDES CLIENTS WITH INTUITIVE, INTERPRETABLE, AND INTERACTIVE BIOMARKER-BASED MODELS

    Bethesda, MD – March 6, 2019 – Precision for Medicine, part of Precision Medicine Group, today announced the acquisition of SimplicityBio, adding artificial intelligence to Precision’s QuartzBio™ multiomic data integration and informatics platform. The addition of an artificial intelligence engine to QuartzBio provides Precision’s clients the most robust, sophisticated end-to-end solution for the “big data” challenge observed in biomarker-guided drug development—furthering their mission of maximizing the value and utility of biomarker data generated in the course of a clinical trial.

  • News

    Precision Medicine Group Acquires Stern Investor Relations, Inc.

    Strengthens Precision’s Position as Leading Partner to Pharmaceutical and Life Sciences Companies at All Life Cycle Stages

    Bethesda, MD – December 17, 2018 – Precision Medicine Group, LLC. (Precision) today announced it has acquired Stern Investor Relations, Inc. (Stern IR), a leading investor relations firm for entrepreneurial biotechnology and healthcare companies. With this acquisition, Precision significantly expands its capabilities to include a complete range of strategic communication services aimed at facilitating capital formation and enhancing client visibility and productive interactions with the financial community. Stern IR supports more than 70 companies in the entrepreneurial biotechnology and healthcare sectors, and its core competencies include creation of investor relations strategy aimed at lowering the cost of capital, positioning and messaging development, relationship building with the financial community, and seamless tactical execution.

  • News

    Further Expansion Into Liquid Biopsy Space Eyed by Precision for Medicine With Recent Acquisition

     

    Precision’s Senior VP, Darren Davis interviews with GenomeWeb to discuss the recent acquisition and merging of ApoCell with Precision for Medicine.

  • Thought Leadership

    Clinical Omics - Unlocking the Value of Complex Biomarker Data

    In this article, our experts are asked to explore biomarker data trends and challenges, and share how drug developers evaluating biomarkers in early-phase studies can quickly realize the full value of the collected data.

  • Thought Leadership

    The Changing Clinical Evidence Requirements Under IVDR

     

    Precision’s Karen Richards and Mona Dean discuss key elements of clinical requirements per the In Vitro Diagnostic Regulation (IVDR) and clinical planning. The IVDR emphasizes the need for manufacturers to demonstrate the clinical evidence for all medical devices.

  • Thought Leadership

    Circulating Tumor Cells Detected from Angiosarcoma Cancer Patients with use of ApoStream® Technology in a First-of-its-kind Study

    PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA

    HOUSTON, TX – November 14, 2018 – Precision for Medicine and TRACON Pharmaceuticals (NASDAQ:TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell’s proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study, titled Detection of Endoglin-Expressing CTCs in Patients Enrolled in an Adaptive Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), is the first of its kind to show the detection and capture of CTCs from angiosarcoma cancer patients. Interim study results were presented at the Connective Tissue Oncology Society (CTOS) annual meeting in Rome, Italy.

  • News

    7 predictions for how clinical trials will look in 10 years

     

    The way clinical trials are being run is gradually changing with the implementation of new technologies. AI, wearables, virtual and in silico trials, digital biomarkers and personalized medicine are all likely to play a major role in the future of clinical trials.

  • Thought Leadership

    Clinical trials in 10 years: Data driven personalized studies

     

    Our President, Patricia Devitt-Risse, looks at how implementing new technology will change how clinical trials are run and predicts how studies will look in 10 years.

  • News

    Precision for Medicine Acquires Liquid Biopsy and Tissue Profiling Pioneer ApoCell

    ADDITION OF HOUSTON-BASED LAB WILL INCLUDE PROPRIETARY APOSTREAM® LIQUID BIOPSY TECHNOLOGY,  FURTHER EXPANDING PRECISION’S LARGE ARRAY OF BIOMARKER CAPABILITIES

    Bethesda, MD – October 16, 2018 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Houston-based ApoCell, a next-generation lab specializing in the identification and analysis of biomarkers. The acquisition adds the ApoStream® liquid biopsy technology and deep expertise in tissue profiling to Precision’s robust suite of specialty laboratory and biomarker informatics services. Providing these advanced capabilities to clients further positions Precision as a scientific frontrunner in the rapidly expanding precision medicine space.

  • Thought Leadership

    Cancer Trials: Making the Most of Biomarkers

    Biomarkers are becoming increasingly important in oncology clinical trials, as they offer a route to more effective (and cost-effective) targeted therapies. Precision’s David Parker, PhD discusses the evolving role of biomarkers in cancer drug development.

  • News

    Eight Top Oncology Drug Approvals

     

    Here is a list of the top oncology drug approvals that give us and patients hope.

    To see the full list, please click here.

  • Thought Leadership

    Improving Population Health Through Multistakeholder Partnerships

     

    In an article published in AJMC, Precision for Medicine’s Nicole Sweeney and David Parker and Precision Health Economics’ Bapu Jena discuss how developing innovative multistakeholder partnerships can improve population health. In this article they provide insight into challenges, barriers to and opportunities for collaboration to address the recent payment and delivery reforms.

  • News

    Precision For Medicine Expands Into Central and Southeastern Europe; Surpasses 300 Employees Throughout UK and EU

    ACQUISITION OF ARGINT INTERNATIONAL ESTABLISHES PRECISION’S SERVICES ACROSS EUROPE WITH STRONG PRESENCE IN HUNGARY, POLAND, ROMANIA, SLOVAKIA, AND SERBIA

     BETHESDA, MD – Sept 25, 2018 – Precision for Medicine, part of Precision Medicine Group, has just expanded its global reach through the acquisition of Argint International, a contract research organization based in Budapest, Hungary. The acquisition is part of Precision’s global growth plan; Precision’s European footprint now includes offices in Edinburgh, Paris, Berlin, Geneva, Budapest, Bucharest, Bratislava, and Belgrade.

  • Thought Leadership

    Complying With the new EU IVDR

     

    In May 2017 the In Vitro Diagnostic Regulation (IVDR) was published and with it came new regulations. Karen Richards discusses the processes and plans that need to be developed by In Vitro Diagnostic (IVD) companies to address the new EU In Vitro Diagnostic Regulations (IVDRs) in advance of their coming into full force in 2022.

  • News

    Precision for Medicine, Oncology and Rare Disease Shortlisted as Finalist for Best Specialist CRO by OBN Awards

     

    We are pleased to announce that the OBN Awards has shortlisted Precision for Medicine, Oncology and Rare Disease as a finalist for Best Specialist CRO!

  • News

    With Drug-Diagnostic Co-Development, Firms Must Ensure Priorities, Goals Align

    As knowledge around biomarkers grows, more drugs are coming onto the market with FDA-approved labels indicating their use with a particular diagnostic test. With most manufacturers nowadays choosing not to develop their own companion diagnostics but rather to partner with an outside firm, pharma companies need to be able to incorporate a diagnostic strategy into their drug development approach so they are able to identify the appropriate patient population at launch and get their drug to as many people as possible.

  • Thought Leadership

    CMS Decision Helps Unlock the Potential of Next-Generation Testing

     

    Precision’s David Parker, PhD covers key takeaways for the oncology community following the Centers for Medicare & Medicaid (CMS) recent announcement on final national coverage determination (NCD)1 expanding coverage for next-generation sequencing (NGS) tests used as companion diagnostics for patients with cancer.

  • Events

    Visit our booth at ESMO!

    Join Precision at the annual ESMO 2018 Congress @ booth #162, October 19-23 in Munich, Germany. Our clinical and translational oncology experts have over 18+ years of oncology research experience and can help you optimize every aspect of your trial.

  • Thought Leadership

    Beyond the hype of clinical trial innovation is a back room of nerds thinking about your product

     

    In a recent survey by KNect365 Life Sciences we explore the excitement in clinical trial innovation. A key takeaway from their survey is that many see change coming and know they need to alter their course, but few have done so or know what to do next.

  • News

    Three Ways Gene Therapy is Improving Cancer Care

     

    Could the future of cancer therapy be gene therapy? When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Learn about ways this expanding area is improving cancer care.

  • News

    Precision for Medicine's Epigenetic Immune Cell Diagnostic Tool Epiontis ID™ Shows Promise in Detecting Severe Immune Diseases Not Currently Identified in Newborn Screenings

    Press release below. To access the published paper, free of charge, click here and download this novel research.

  • News

    Precision Medicine Group Acquires Scientific and Medical Communications Company, ETHOS

    EXPANDED EMPHASIS ON INTERPRETING THE SCIENCE OF COMPLEX MEDICAL INNOVATIONS
    BOLSTERS PRECISION’S CAPABILITIES TO SUPPORT COMMERCIAL AND R&D CLIENT BASE

    Bethesda, MD – Tuesday, July 10, 2018 – Precision Medicine Group, LLC., announced it is acquiring ETHOS Health Communications, a Pennsylvania-based agency specializing in the interpretation and communication of innovative medical science. The acquisition of ETHOS, which informs physicians, providers and other stakeholders through medical affairs- and marketing-based scientific content, allows Precision to offer its clients a significantly expanded cadre of doctoral-level science and medical communications specialists.

  • Events

    Join us at the American Association for Clinical Chemistry Expo, July 29 - Aug 2 Booth #1453

    We look forward to seeing you in Chicago! Stop by booth #1453 to learn more about how our IVD CRO services provides an agile, customer-focused, tailored solution to the needs of the IVD industry.

  • Thought Leadership

    The Evolving Role Of Biomarkers In Oncology Clinical Trial Design

     

    In the second installment of the Clinical Leader series, Precision’s David Parker discusses the incorporation of biomarkers in oncology clinical trials to achieve both clinical and commercial success in today’s value-focused reimbursement environment. The Clinical Leader series explores the shift from volume- to value-based healthcare reimbursement in the United States. 

  • Events

    Join us at Arena’s Clinical Operations in Oncology Trials, July 11-12 in Boston

    We look forward to seeing you in Boston! Make sure you catch Patricia Devitt-Risse’s presentation on Proactive Planning to Optimize Biomarker and Diagnostics Collection, Wednesday, July 11th at 9:00 a.m. 

  • Thought Leadership

    David Parker on Managing Care in the Wave of Precision Medicine

     

    Precision’s David Parker participated in the AMCP Partnership Forum to provide recommendations for best practices in evidence generation and collection and trial designs in precision medicine.

  • Thought Leadership

    CMS to Cover Next-Gen Sequencing for Cancer: Implications for MCOs

     

    Precision for Medicine’s David Parker and Karen Richards review the recent CMS announcement of a final national coverage determination (NCD) expanding coverage for next-generation sequencing (NGS) tests used as companion diagnostics for determining cancer patients’ eligibility for appropriately indicated drugs.

  • News

    Sheila Antonio talks strategies and challenges in Knect365's Clinical Data Series.

     

    As part of KNect365’s Clinical Data Collection and Management Series, Sheila explores not only the most effective new technologies and innovative strategies being used to collect clinical data, but the biggest challenges we face as well.

  • Events

    Precision and FierceBiotech’s Free Live Webinar and Overcome Data Chaos With QuartzBio™ Available Now

    Precision and FierceBiotech’s free live webinar—Overcome Data Chaos With QuartzBio: Turn Biomarker Data Sets Into Actionable Insights—is now available on-demand

  • Thought Leadership

    Dr. Tandy Tipps Talks Critical Factors & Strategies for Choosing the Right Site for Oncology Trials

     

    In an interview with KNect365, Precision Oncology’s Dr. Tandy Tipps, VP, Oncology Site Network, tells you how to match the right sites to the right trials and enable the opportunities of precision oncology trials. 

  • Events

    PFM at AAI 2018

     

    Precision for Medicine is proud to be a sponsor of and exhibiting at Immunology 2018, the annual meeting of the American Association of Immunologists, May 4-8 in Austin. Please visit us at Booth 826 to meet with our experts!

  • Events

    Precision Participating in Oracle Health Insurance Round Table

     

    Precision will participate in a panel at the upcoming Oracle Industry Connect event on April 9-11 in New York City.

  • Events

    PFM Exhibiting at PEGS 2018

     

    Precision for Medicine will be exhibiting and VP Immune Monitoring & Specialty Lab Services Thomas Kleen, PhD, will be presenting on immune monitoring at PEGS 2018, April 30 to May 4 in Boston. Please visit us at Booth 429 to meet with our experts!

  • Events

    PFM at CYTO 2018

     

    Precision for Medicine will be sponsoring and exhibiting at CYTO 2018, April 29 to May 2, in Prague. Please visit us at Booth 79 to meet with our experts!

  • Events

    Judi Smith Will Be Presenting At AMDM in April

    Judi Smith, MS, vice president, In Vitro Diagnostics and Quality, will present a case study on planning for EU in vitro diagnostics regulation at the upcoming Association of Medical Diagnostics Manufacturers 45th Annual Meeting, April 16-19, in Bethesda, Maryland.

    Register Here

  • Thought Leadership

    Precision’s Kohler, Quigley, Guennel on Meeting FDA Specialty Lab Data Requirements

     

    With increased biomarker and specialty lab data being incorporated into FDA submissions, drug developers are running into challenges as they prepare data that comply with new regulatory requirements.

  • News

    Smith and Richards Recap the FDA's Workshop on Troponin Assays in Regulatory Focus

     

    Precision for Medicine’s Judi Smith and Karen Richards highlight key takeaways from the FDA’s Cardiac Troponin Assays workshop.

  • News

    Precision for Medicine Named Top 20 Bioinformatics Solution Provider

     

    We are proud to be recognized as one of the Top 20 Bioinformatics Solution Providers by respected technology trends magazine CIO Applications.

  • Thought Leadership

    Kohler and Guennel Discuss Biomarker Drug Development & New FDA Data Requirements in Regulatory Focus

     

    Precision for Medicine’s Jared Kohler and Tobias Guennel highlight the challenges for researchers pursuing biomarkers and specialty lab data that meet new FDA regulatory standards.

  • Events

    13th Annual Biomarkers Congress

     

    February 15th-16th

    Manchester, UK

    Precision for Medicine will be exhibiting at the 13th Annual Biomarkers Congress from February 15-16 in Manchester, United Kingdom.
    https://www.biomarkers-congress.com/

  • Events

    Molecular Med Tri-Con

     

    February 11th-16th

    San Francisco, CA

    Precision for Medicine will be exhibiting and Deborah Phippard, PhD, SVP, Research, will be speaking at the Molecular Med Tri-Con conference from February 11-16 in San Francisco.
    http://www.triconference.com/

  • Events

    Q1 Dx Coverage & Reimbursement Conference

     

    February 6th-7th

    San Diego, CA

    Precision for Medicine will be exhibiting and David Parker, PhD, SVP, Diagnostics Solutions, will be speaking at the Q1 Dx Coverage & Reimbursement conference from February 6th- 7th https://www.q1productions.com/dxreimbursementeast/

  • News

    Precision Biomarker Data Management Expansion Detailed in GenomeWeb

     

    In its weekly digest, GenomeWeb reports on Precision for Medicine’s expansion of biomarker data management and translational informatics services.

  • Events

    Society for Laboratory Automation and Screening (SLAS)

     

    February 3rd-7th

    San Diego, CA

    Precision for Medicine is proud to be exhibiting at the upcoming SLAS conference in San Diego from February 3rd-7th.

    Stop by booth #1113 to meet our experts and enjoy a refreshment.

    https://www.slas2018.org/

  • Events

    GTC ImmunoTX Summit

     

    January 30th- 31st

    San Diego, CA

    Precision for Medicine will be sponsoring and Ulrich Hoffmueller, PhD, MBA, VP, Immune Monitoring Solutions will be speaking at the GTC ImmunoTX Summit from January 30-31 in San Diego.

     

  • Thought Leadership

    Chief Medical Officer Gerry Messerschmidt Discusses Cancer Vaccine Development in Biocompare

     

    Chief Medical Officer Gerry Messerschmidt authors a new commentary in Biocompare outlining critical success factors toward cancer vaccine development.

  • News

    Precision for Medicine Expands Services in Europe, Announces Next Generation Biomarker Data Management and Translational Informatics Platform

    ADDITION OF GENEVA-BASED TEAM COMPLEMENTS U.S. EXPERTS;
    QuartzBio RELEASE ACCELERATES BIOMARKER DATA MANAGEMENT
    AND TRANSLATIONAL INFORMATICS CAPABILITIES

    Bethesda, MD and Geneva, Switzerland – January 9, 2018 – Precision for Medicine, part of Precision Medicine Group, today announced it is expanding its biomarker data management and translational informatics services into Europe. The addition of a Geneva, Switzerland–based team of experts complements Precision’s US offerings to provide clients with truly global translational research services. The Geneva team also gives Precision another European operational base, continuing Precision’s active international expansion.

  • News

    Precision Medicine Group Lands Major New Investment

    BERKSHIRE PARTNERS AND TPG GROWTH CO-LEAD $275 MILLION INVESTMENT AS THE COMPANY POSITIONS FOR THE NEXT PHASE OF GROWTH

    BETHESDA, MD — December 19, 2017 — Precision Medicine Group (PMG) announced today that it has reached an agreement for a $275 million investment that positions the company for the next phase of growth.

  • Thought Leadership

    Precision Oncology’s Messerschmidt Video Interview: Promising Times in Rare Cancers

     

    Rare Disease Report interviews Chief Medical Officer Gerald Messerschmidt while at the American Society of Hematology Annual Meeting.

  • Thought Leadership

    Precision's Messerschmidt Discusses New Myeloma Therapies in Managed Healthcare Executive

     

    In the current edition of Managed Healthcare Executive, Precision Oncology’s chief medical officer Dr. Gerry Messerschmidt comments on the unprecedented pace of outcomes improvements.

  • News

    Precision Value & Health Announces Formation of Global Market Access Consultancy—Precision Xtract

    NEW ALIGNMENT OF INDUSTRY-LEADING CONSULTING AND DATA SERVICES PROVIDES UNIFIED HEALTH ECONOMICS AND OUTCOMES RESEARCH, PRICING, GLOBAL MARKET ACCESS, AND PAYER ANALYTICS TO SUPPORT PHARMACEUTICAL AND LIFE SCIENCES INNOVATORS

    New York, NY – November 2, 2017 – Precision Value & Health today announced the formation of Precision Xtract—a new, focused alignment of the company’s global market access consulting and data services. The move is designed to offer clients an interconnected team of specialists developing strategies, tools, and tactics in support of next generation approaches to drug development and product value demonstration.

  • Thought Leadership

    Messerschmidt Addresses the Future of Cancer Vaccines in FiercePharma

    Precision Oncology’s Gerry Messerschmidt, MD, talks with FiercePharma’s Eric Sagonowsky and predicts we’ll see licensed cancer vaccines in the next 2 to 3 years.

  • Thought Leadership

    Precision's Messerschmidt and Schafer Discuss Cost of New Gene Therapies With Managed Healthcare Executive

     

    In Managed Healthcare Executive, Precision Oncology’s Gerald Messerschmidt and Precision for Value’s Jeremy Schafer are tapped to provide their expert perspectives on the cost and value challenges facing the new class of CAR T-cell therapies.

  • News

    Ethan Leder’s Puerto Rico Relief Efforts Shared by NPR

     

    NPR describes the efforts of Precision Medicine Group cofounder Ethan Leder to deliver desperately needed medical and emergency supplies to Puerto Rico.

  • News

    Ethan Leder Spearheads Effort to Deliver Medical and Emergency Supplies to Puerto Rico

     

    Precision Medicine Group cofounder Ethan Leder is featured in the Johns Hopkins University publication HUB, detailing his recent efforts to help personally deliver desperately needed medical and emergency supplies to Puerto Rico in the aftermath of Hurricane Maria.

  • Thought Leadership

    Q&A With Precision’s Scott Marshall in Drug Discovery & Development: Biomarkers Can Inform Early-Stage Clinical Trial Design

     

    Precision for Medicine’s Scott Marshall, managing director, Translational Informatics & Diagnostics, participates in a Q&A with Drug Discovery & Development’s Ryan Bushey. Marshall outlines the benefits biomarkers can yield in early-stage trials.

    To read the complete interview, click here.

  • Thought Leadership

    David Parker Discusses CDx Development in Clinical OMICs

     

    David Parker, SVP, Diagnostics Solutions, was interviewed along with a panel of experts on changes in CDx development in Clinical Omics.

  • News

    GenomeWeb Reports on Epiontis Acquisition

     

    GenomeWeb covers Precision for Medicine’s recent acquisition of Epiontis, summarizing Precision’s busy year of growth and highlighting the expanded capabilities now available to clients.

  • News

    Precision for Medicine Acquires Epiontis—a Leading Immune Monitoring and Epigenetic Technology Service Provider

    ADDITION OF BERLIN-BASED LAB EXPANDS PRECISION’S LARGE ARRAY OF IMMUNE MONITORING CAPABILITIES AND BOLSTERS GLOBAL FOOTPRINT

    Bethesda, MD and Berlin, Germany – October 4th, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Berlin-based Epiontis GmbH, a next-generation European specialty laboratory providing immune monitoring services through a novel, patent-protected epigenetic platform. The acquisition adds Epiontis’s unique epigenetic technology and expertise to Precision’s robust suite of immune monitoring services for clinical trials, bringing additional value and capabilities to clients. It expands Precision’s growing global footprint and further positions the company as a scientific frontrunner in the rapidly expanding precision medicine space.

  • Thought Leadership

    Speier Discusses FDA and mHealth Utilization with Applied Clinical Trials

     

    With the growth and increasing applications of mHealth come the need to regulate, and the biopharmaceutical industry and regulatory bodies such as the FDA are coming together to develop frameworks for mHealth utilization in clinical trials.

  • News

    Precision Medicine Group Announces Formation of Comprehensive Services Offering–Precision Value & Health

    NEW ALIGNMENT OF INDUSTRY-LEADING SERVICES PROVIDES INTEGRATED SCIENCE, RESEARCH, TECHNOLOGY, ANALYTICS, AND COMMUNICATIONS TO INNOVATORS IN LIFE SCIENCES

    Bethesda, MD – September 21, 2017 – Precision Medicine Group, a specialized services company supporting next generation approaches to drug development and commercialization, today announced the formation of Precision Value & Health—a focused set of complementary services working in concert to help pharmaceutical and life sciences clients establish the clinical, economic, and humanistic value of innovative therapies to payers, healthcare professionals, and patients.

  • Thought Leadership

    Choosing the Right Partner: Special Sample Needs For In Vitro Diagnostics

     

    Is a sample just a sample? You’d be surprised. Karen Richards, vice president, In Vitro Diagnostics and Quality, discusses the importance of sample collection and many of the sample source and trial design challenges facing in vitro diagnostics innovators:

  • News

    Clark Discusses Agility Clinical Acquisition With ClinicalOMICS

     

    In the latest edition of ClinicalOMICS, Precision for Medicine President Chad Clark elaborates on the recent acquisition of rare and orphan CRO Agility Clinical.

  • News , Thought Leadership

    Precision for Medicine Acquires Leading Rare Disease CRO, Agility Clinical

     

    Extending Precision’s Capabilities Into One of the Fastest Growing Areas of Drug Development

    Bethesda, MD and Carlsbad, CA – September 6, 2017 – Precision for Medicine, part of the Precision Medicine Group, announced today it has acquired Agility Clinical (“Agility”), the leading contract research organization (CRO) focused specifically on clinical development of rare disease and orphan therapies. The acquisition creates the first comprehensive, fully integrated orphan therapy clinical development services provider, combining the highest standards in global clinical trial execution and biometrics expertise with sophisticated biomarker and specialty lab capabilities.

  • Thought Leadership
    Get the Brief

    Barriers to Progress: Why Personalized Medicine Hasn't Developed for Chronic Conditions

    Chronic conditions—asthma, hypertension, diabetes, depression, and others—are widely prevalent and have a significant impact on long-term healthcare costs. Diagnostic targeting of drug therapies in treatment may improve response rates and adherence, producing both clinical and economic benefits. But first, some current care delivery and infrastructure paradigms have to change.

  • News

    Precision's Messerschmidt Talks Immunotherapy with ASCO Post

     

    Precision Oncology Chief Medical Officer Gerald Messerschmidt sits down to talk with ASCO Post‘s Ronald Piana regarding the future of immunotherapy.

  • News

    Chad Clark Talks EU Expansion With Clinical OMICs

     

    Precision for Medicine President Chad Clark speaks with Alex Philippides of Clinical OMICs to discuss Precision’s European expansion.

  • Thought Leadership

    Precision’s Clark and Marshall Advocate for Biomarker Data Management in Bioscience Technology Online

     

    Precision for Medicine’s Chad Clark, President, and Scott Marshall, Managing Director of Biomarker and IVD Analytics, contribute a new commentary for Bioscience Technology Online on the challenges of biomarker data management.

  • News

    Precision for Medicine Expands Its Global Footprint for Oncology Development Services

     

    Leadership in Place; Clinical Operations Teams Growing Throughout Europe

    Bethesda, MD – July 6th, 2017 – Precision for Medicine today reported important progress in its global expansion plan. Precision for Medicine, with its oncology research team Precision Oncology, is rapidly expanding its global footprint to better serve clients developing oncology treatments. Investment in executive leadership and operational teams are underway across Europe, providing integrated, full-service clinical trial execution services throughout the continent.

  • Thought Leadership
    Get the Brief

    EU IVD regulations now align with US. Are you ready?

    Across the European Union, Notified Body (NB) review is now required—along with significant technical and quality documentation. The transition to this new paradigm may begin as soon as Q4 2017, and it will have a meaningful impact on product launch plans and timelines.

  • News

    Precision Oncology's Messerschmidt in Managed Healthcare Executive Q&A: Innovative Strategies Help Fight Multiple Myeloma

     

    In Managed Healthcare Executive, Precision Oncology Chief Medical Officer Dr. Gerry Messerschmidt discusses the many recent advances in treating multiple myeloma.

  • Events

    Drug Information Association (DIA) 2017

    June 18-22, 2017

    McCormick Place

    Chicago, IL

    Booth #2310

    Precision will be exhibiting again at DIA this summer in Chicago. Look for us on the exhibitor floor in Booth #2310.

  • Events

    mHealth for Clinical Trials 

     

    June 12-14, 2017

    Westin Boston Waterfront

    Boston, Massachusetts

    Austin Speier, Director of Emerging Technologies with Precision for Medicine, will be speaking at the mHealth for Clinical Trials conference in Boston this June.

  • Events

    American Society of Clinical Oncology (ASCO)

    American Society of Clinical Oncology (ASCO)

    June 2-6, 2017

    McCormick Place

    Chicago, IL

    Booth #2124

    Precision will be exhibiting again at ASCO this summer in Chicago. Look for us on the exhibitor floor in Booth #2124 meet with our oncology experts.

  • Events

    Americas Antibody Congress

     

    May 23-24

    Hilton San Diego Resort & Spa

    San Diego, California

    Rajiv Mahadevan, Managing Director with Precision for Medicine, will be speaking at the Americas Antibody Congress in San Diego this May.

  • Events

    AdvaMed Payment Policy Conference

     

    May 16-17

    Hyatt Regency Baltimore Inner Harbor

    Baltimore, MD

    David Parker, SVP Dx Solutions Precision for Medicine, will be speaking on a panel at the AdvaMed Payment Policy Conference this May in Baltimore. The panel will explore “Generating Real World Evidence for Coverage and Payment: Practical Approaches for MedTech”.

  • News

    Precision for Medicine and Philips Team Up to Achieve FDA Approval of the First Digital Pathology Solution for US Diagnostic Use

     

     

    Congratulations to the clinical trial and regulatory teams at Precision for Medicine: The FDA has just announced that the Philips PIPS (Philips IntelliSite Pathology Solution) has been approved through the de novo premarket review pathway as the first digital pathology solution for primary diagnostic use in the US.

    This regulatory clearance signals a significant leap forward for the pathology services industry, and is expected to greatly boost adoption of digital pathology and collaboration.

    Precision provided instrumental support to Philips in achieving this approval, monitoring the pivotal trial and working directly on the FDA strategy, including the successful effort to down-classify the system from a PMA Class III device to a Class II device (representing devices of a new type with low-to-moderate risk). This down-classification not only shortened the review time, but also reduces the regulatory burden going forward and streamlines the process for bringing incremental innovations to the US market.

    For more information, click the link below to view the FDA press release.

  • Thought Leadership

    Precision's David Parker Discusses CDx Development Relationships with Clinical Omics

     

    Precision’s David Parker, PhD, senior vice president, diagnostics solutions, recently spoke with Clinical OMICs Editor-in-Chief Chris Anderson about some of the issues inherent in CDx development relationships.

  • News

    Precision for Medicine and Precision Oncology CDM/EDC Teams Win Oracle Award

     

    Congratulations to our CDM and EDC teams from Precision Oncology and Precision for Medicine for being recognized by Oracle with the Excellence in Industry Service–Americas Award for 2017! Oracle was pleased to recognize Precision as an industry-leading, niche CRO dedicated to oncology studies and precision medicine initiatives. Another great example of the integration synergy generated on an ongoing basis—with Precision Oncology providing Oracle with clinical data management and Precision for Medicine providing electronic data capture builds.

  • Thought Leadership

    Pat Devitt Risse in Life Science Leader: Bet On Biomarkers for Better Outcomes

     

    In the latest edition of Life Science Leader, Precision Oncology president Pat Devitt Risse contributes a new guest column: “Bet On Biomarkers for Better Outcomes.” In the article, Pat advocates for greater use of biomarkers used to accurately pinpoint the patient population that will benefit from a drug during clinical trials.

  • Events

    Protein Engineering Summit (PEGS)

    Protein Engineering Summit (PEGS)

    May 1-4, 2017

    Boston, MA

    Booth #420

    Precision for Medicine will be exhibiting and presenting a poster at PEGS 2017 from May 1-4, 2017 at the Seaport World Trade Center in Boston, MA.

    Poster information:
    Author: Angelina Bisconte, Scientific Information Developer, Precision For Medicine
    Title: Precision in the Detection of Myeloid-derived Suppressor Cells (MDSCs)

  • Events

    AAPS: Biotech

    AAPS: Biotech

    May 1-3, 2017

    San Diego, CA

    Booth #516

    Precision for Medicine will be exhibiting at the National Biotechnology Conference in San Diego.

  • Events

    Clin Ops in Oncology Trials - West Coast

    Clin Ops in Oncology Trials - West Coast

    April 11-12, 2017

    Burlingame, CA

    Precision Oncology will be exhibiting and presenting a session at Arena’s Clinical Operations in Oncology Trials – West Coast conference in Burlingame, CA.

    Session on April 11ᵗʰ : Jeff Seroskie, MS, Vice President, Precision Oncology will be speaking on how “Precision medicine is ‘bending the curve’ of drug development” in oncology.

  • Thought Leadership
    Get the brief

    Perspective: Convergence of CLIA and FDA Requirements: A Rationale Shift in the Regulatory Paradigm

    The laboratory developed test (LDT) has proven to be a flexible, quick, lower-investment assay commercialization option—yet the evolving regulatory landscape still threatens to alter that. How can you navigate these tougher requirements while maximizing efficiencies? This brief will help you plan and prepare, ensuring that your quality systems and validation studies support FDA and CLIA requirements as they evolve—and that you stay a step ahead of regulatory demands.

  • Thought Leadership
    Get the brief

    6 Critical Factors for Achieving Approval of Oncology Drugs

    In this high-stakes, high-velocity environment of oncology drug development and regulatory approval, biotech companies face significant competitive pressure to move quickly from first-in-human to proof-of-concept. Are you following the right imperatives to design smarter clinical trials? Find out how. In this brief you’ll get breakthrough insights—based on real-world examples from successful oncology trials—that will help you deliver speed, strength, and the best evidence for ensuring approval and reimbursement.

  • Thought Leadership
    Get the brief

    Harmonizing Biomarker Data

    Today’s clinical trials generate and capture hundreds of thousands of data points—spanning multiple types of biomarker data generated by multiple vendors and diverse assays. Effective management of that data is not only foundational to success, it enables you to produce an order-of-magnitude reduction in time and cost, mitigate major risks for interim and final study deliverables, and be prepared to meet new FDA requirements. Find out how in this brief prepared by the experts at Precision for Medicine.

  • News

    Precision Oncology’s Messerschmidt on Protocol Development in PharmaVOICE

    Precision Oncology’s Dr. Gerald Messerschmidt discusses clinical protocol development with Denise Myshko for PharmaVOICE.

  • Thought Leadership

    Commentary: The Challenges of Harmonizing Biomarker Data: Why Trial Success Depends on It

    Commentary: The Challenges of Harmonizing Biomarker Data: Why Trial Success Depends on It

    Precision for Medicine’s Scott Marshall and Jared Kohler address the challenges and importance of harmonizing biomarker data in a new editorial for Genetic Engineering and Biotechnology News (GEN). Scott and Jeremy make the point that generating, tracking, and harmonizing biomarker data and clinical data in real time to inform timely decision-making is critical in modern clinical trials.

  • Events

    Molecular Medicine Tri-Con 2017

    Molecular Medicine Tri-Con 2017

    February 20-24, 2017

    San Francisco, CA

    Booth #201

    Precision for Medicine will be exhibiting at Molecular Medicine Tri-Con 2017 from February 20-24, at the Moscone North Convention Center in San Francisco, CA.

  • Events

    Q1 Dx Coverage & Reimbursement Conference

    Q1 Dx Coverage & Reimbursement Conference

    February 9- 10, 2017

    San Diego, CA

    Precision for Medicine will be exhibiting and David Parker, PhD, SVP, Diagnostics Solutions, will be presenting a case study at the Q1 Dx Coverage & Reimbursement conference from February 9-10, at the Andaz San Diego.

  • Events

    SLAS 2017

    SLAS 2017

    February 4-8, 2017
    Washington, DC

    Precision for Medicine exhibited and presented a poster at SLAS2017 in Washington, DC Feb 4-8.

    Scott Marshall, PhD, Managing Director Analytics presented his work in “Leveraging a Series of Studies to Optimize Success in CDx Development” at the show

    Download the poster below to learn more, or email info@precisionformedicine.com to schedule a meeting.

     

  • Thought Leadership

    Briefing: Best Practices for the Expedited Start-Up of Oncology Trials

    Precision subject matter expert, Tandy Tipps, highlights how oncology sites can work with their development partners to make study start up achievable within 90 days.

  • Events

    World Precision Medicine Congress

    Date: November 14, 2016 – November 15, 2016

    Washington, DC

    Precision for Medicine is proud to be a platinum sponsor at the World Precision Medicine Congress

    Mark Clein, Co-Founder, Chief Executive Officer, Precision Medicine Group will be chairing Day Two of the event – November 15th. Chad Clark, President, Precision for Medicine will also be presenting at 9.30am on Day Two (November 15th) on “Precision approvals: How biomarkers are blurring the lines in clinical trials and accelerating commercial launch.”

  • Events

    Association of Molecular Pathology (AMP) 2016

    Date: November 10, 2016 – November 12, 2016

    Precision for Medicine will be exhibiting at AMP from November 10-12 at the Charlotte Convention Center.

    Precision has developed specialized IVD and medical device trial services to fully implement and support your clinical research plan. We have the expertise to manage the full clinical study program and can take initiative in all aspects of program execution. Our Dx experts from clinical operations to regulatory and market access will be on hand at AMP to help you learn more, visit us at booth #1819!

  • Events

    Society for Immunotherapy of Cancer (SITC) 2016

    Society for Immunotherapy of Cancer (SITC) 2016

    Date: November 09, 2016 – November 13, 2016

    Precision for Oncology will be exhibiting at SITC from November, 9-13 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland.

    Precision is able to provide a one-of-a-kind oncology solution which includes integrated specialty labs services, clinical trials design and operations, and advanced biomarker analytics. Our Immunology and Clinical Trial experts will be on hand at SITC to help you learn more, visit us at booth #240!

  • Events

    World CDx 2016

    World CDx 2016

    Date: October 18, 2016 – October 21, 2016

    Precision for Medicine will be exhibiting at World CDx from October 18-21, at the Boston Convention and Exhibition Center.

    Stop by booth #14 to meet Precision’s Dx and CDx experts and learn how we can help support your research.

  • Events

    Sixth Annual Association for Value Based Cancer Care Conference

    Sixth Annual Association for Value Based Cancer Care Conference

    Date: September 29, 2016

    Precision Oncology’s Messerschmidt to Moderate AVBCC Panel

    Omni Shoreham Hotel

    Washington, DC

    On September 29th, Precision Oncology’s Dr. Gerald Messerschmidt, M.D, FACP will participate in a panel to be held at the Sixth Annual Association for Value Based Cancer Care Conference. The panel, entitled “Genomics and Personalized Medicine,” is to be moderated by Dr. Messerschmidt and will take place from 10:45am-11:15am.

  • Events

    2016 National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo

    2016 National Association of Specialty Pharmacy (NASP) Annual Meeting & Expo

    Date: September 26, 2016 – September 28, 2016

    NASP Annual Meeting & Expo 2016

    Omni Shoreham Hotel

    Washington, DC

    Precision’s Schafer and Messerschmidt to Participate in NASP Panels

  • Thought Leadership

    Briefing: 3 Advances Driving Oncology Clinical Trial Success

    Briefing: 3 Advances Driving Oncology Clinical Trial Success

    Precision subject matter expert Pat Devitt examines the 3 advances driving oncology clinical trial success in a special editorial for STAT News.

  • Events

    Event: Next Generation Dx Summit

    Event: Next Generation Dx Summit

    Date: August 23, 2016 – August 26, 2016

    Precision for Medicine will be exhibiting in booth #19

    Grand Hyatt Hotel, Independence Ballroom A

    Washington, D.C.

  • Events

    Event: American Association for Clinical Chemistry Annual Meeting

    Event: American Association for Clinical Chemistry Annual Meeting

    Date: July 31, 2016 – August 04, 2016

    American Association for Clinical Chemistry Annual Meeting

    Precision for Medicine will be exhibiting in booth #4027

    Philadelphia Convention Center, Philadelphia, PA

  • Events

    Event: Festival of Genomics

    Date: June 27, 2016 – June 29, 2016

    Festival of Genomics

    Precision for Medicine will be exhibiting at the Festival of Genomics.

    The Festival is one of the largest genomics events, showcasing new research, technology and advances in medicine.

    June 27-29, 2016

    Boston Convention Center, Boston, MA

  • Events

    Event: DIA – 2016

    Date: June 26, 2016 – June 30, 2016

    Drug Information Association 2016

    Philadelphia Convention Center

    Philadelphia, PA

    Precision for Medicine will be exhibiting in booth #1749

  • Events

    Event: ASCO Annual Meeting

    Event: ASCO Annual Meeting

    Date: June 03, 2016 – June 07, 2016

    ASCO Annual Meeting

    Location: McCormick Place, Chicago, IL

    Precision for Medicine will be exhibiting in Booth #23127

  • News

    Press Release: ACT Oncology Wins the PACT 2016 Enterprise Award for Emerging Healthcare Companies

    Press Release: ACT Oncology Wins the PACT 2016 Enterprise Award for Emerging Healthcare Companies

    Flemington, N.J., May 19, 2016 – ACT Oncology announced today it has been awarded the Philadelphia Alliance for Capital and Technologies (PACT) 2016 Enterprise Award for Emerging Healthcare companies. The Enterprise Awards, held annually, are the region’s most prestigious business honors for innovative life sciences and technology companies, leaders, and entrepreneurs.

    The Enterprise Healthcare Emerging Award recognizes companies that are providing an innovative technology solution that has the potential to make a significant and positive impact on a clinical problem in healthcare. The 20th Annual Enterprise Awards comprised 400 companies vying for awards in 10 categories.

  • Events

    Event: Biomarkers & Diagnostics World Congress

    Event: Biomarkers & Diagnostics World Congress

    Date: May 16, 2016 – May 19, 2016

    Biomarkers & Diagnostics World Congress

    Location: Philadelphia Marriott Downtown, Franklin Hall A

    Precision for Medicine will be exhibiting in booth #26

  • News

    After ACT Oncology Buy, Precision Medicine Snaps Up Applied Immunology – FierceBioTech

    After ACT Oncology Buy, Precision Medicine Snaps Up Applied Immunology – FierceBioTech

    Fierce Biotech’s Ben Adams focuses on Precision’s acquisition of Applied Immunology.

  • News

    Press Release: Precision for Medicine Acquires Applied Immunology

    Press Release: Precision for Medicine Acquires Applied Immunology

    Establishes Bay Area Immune-Response Laboratory Capability

    Bethesda, Md. and Redwood City, Calif., May 3, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has acquired Applied Immunology, an established expert in the creation and delivery of custom cell-based and immunoassay solutions. Applied Immunology supports innovative and targeted therapeutics developers across all areas, ranging from immuno-oncology to rare diseases to biosimilars from research to post-approval. Applied Immunology’s client base includes some of the most pioneering new venture-backed startups, along with many major global pharmaceutical firms.

  • News

    Precision for Medicine acquires Applied Immunology – The pharmaletter

    Precision for Medicine acquires Applied Immunology – The pharmaletter

    Chad Clark is quoted in the pharmaletter regarding the recent acquisition of Applied Immunology.

  • Events

    Event: ARMADA Pharmacy Summit

    Event: ARMADA Pharmacy Summit

    Date: May 02, 2016 – May 06, 2016

    Location: Wynn & Encore Hotel
    Las Vegas, Nevada

  • Events

    Event: Bio-IT World Conference and Expo 2016

    Date: April 05, 2016 – April 17, 2016
    Location: Boston, MA

    Precision for Medicine will be exhibited in booth #344 at the Bio-IT World Conference and Expo 2016.

    The event will take place at the Seaport World Trade Center in Boston, MA from April 5-7, 2016.

    Click here to learn more: http://www.bio-itworldexpo.com/

  • Events

    Event: Molecular Diagnostics Europe

    Date: April 05, 2016 – April 07, 2016
    Location: Lisbon, Portugal

    Location: Sheraton Lisbon Hotel and Spa
    Lisbon, Portugal
    Booth #3
    Business Unit: IVD

    http://www.moleculardxeurope.com/

  • Events

    Event: National Comprehensive Cancer Network Annual Conference

    Event: National Comprehensive Cancer Network Annual Conference

    Date: March 31, 2016 – April 02, 2016
    Location: Hollywood, FL

    Precision will be attending the National Comprehensive Cancer Network Annual Conference in Hollywood, FL.

  • News

    Precision for Medicine Acquires ACT Oncology – Medical Marketing & Media

    Precision for Medicine Acquires ACT Oncology – Medical Marketing & Media

    Precision for Medicine Acquires ACT Oncology – Medical Marketing & Media

  • News

    Precision for Medicine Broadens Cancer Trial Offering With ACT Oncology Buy – FierceCRO

    Precision for Medicine Broadens Cancer Trial Offering With ACT Oncology Buy – FierceCRO

    Chad Clark and Pat Devitt speak with Ben Adams from FierceBiotech on the acquisition of ACT Oncology.

  • News

    Press Release: Precision for Medicine to Acquire ACT Oncology

    Press Release: Precision for Medicine to Acquire ACT Oncology

    Establishes Leading Platform for Precision Medicine Oncology Research

    Bethesda, Md. and Flemington, N.J., March 22, 2016 – Precision for Medicine, part of the Precision Medicine Group, announced today that it has executed a binding agreement to acquire ACT Oncology, the leading contract research organization (CRO) specializing exclusively in the field of oncology. ACT Oncology provides drug development services focused on the design and execution of clinical trials on behalf of innovative life sciences companies and not-for-profit patient organizations.

  • News

    R&D Spending by Drug Companies – Pharmaceutical Compliance Monitor

    R&D Spending by Drug Companies – Pharmaceutical Compliance Monitor

    By Ilyssa Levins

    R&D Spending by Drug Companies

    You may have read my February 2016 PCM article that proposed a six-step plan to deflect criticism about pharmaceutical drug costs. I provided hard data to support the value of our industry and will now continue to expand upon our value by addressing the significant role of America’s biopharmaceutical companies in bringing new medicines to patients.

  • News

    Precision for Medicine Transforms Big Data into Actionable Information – BioIT World

    Precision for Medicine Transforms Big Data into Actionable Information – BioIT World

    BioIT World’s Paul Nicholas examines Precision for Medicine’s new PATH immuno-analytics platform.

  • Events

    Event: 9th Semi-Annual Diagnostic Coverage and Reimbursement Conference

    Date: February 08, 2016 – February 09, 2016
    Location: San Diego, CA

    Precision will be exhibiting and speaking at the 9th Semi-Annual Diagnostic Coverage and Reimbursement Conference.

    Speaker: David Parker, PhD, Vice President, Integrated Market Access

  • Events

    Event: Society for Laboratory Automation and Screening (SLAS) 2016

    Event: Society for Laboratory Automation and Screening (SLAS) 2016

    Date: February 07, 2016 – February 09, 2016
    Location: Orlando, FL

    Breakout Session, February 9th    (two concurrent): Opposing Influences of Evidence and Market Forces in Pharmaceutical Pricing and Payer Net Cost

    Larry Blandford – Senior Vice President & Managing Partner, Precision for Value

    Steve Carter – Vice President, Pricing and Market Access, Precision for Value

  • News

    Precision for Medicine receives $75 million investment – Medical Marketing & Media

    TPG’s $75 million investment in Precision Medical Group is featured in Medical Marketing & Media.

  • News

    TPG Invests $75 Million into Precision For Medicine – PharmaLive

    TPG Invests $75 Million into Precision For Medicine – PharmaLive

    PharmaLive covers TPG’s significant investment in Precision Medicine Group

  • News

    TPG bets $75M on Pharma Service Provider Precision for Medicine – FierceCRO

    TPG bets $75M on Pharma Service Provider Precision for Medicine – FierceCRO

    TPG partner Kevin Hobart discusses the equity firm’s investment in Precision Medicine Group with Damian Garde for Fierce Biotech,

  • News

    Press Release: TPG Growth Invests $75 Million in Precision for Medicine

    Press Release: TPG Growth Invests $75 Million in Precision for Medicine

    Leader in Healthcare Investing Acquires Stake in Growing Pharmaceutical Services Company

    Fort Worth, Texas, San Francisco and Bethesda, MD — December 22, 2015 — TPG Growth, the middle market and growth equity investment platform of TPG, a leading global private investment firm with approximately $70 billion of assets under management, today announced a $75 million investment in Precision for Medicine, Inc. Additional details of the transaction were not disclosed.

  • News

    Congress Considers Regulation of Lab-Developed Tests – Roll Call

    Congress Considers Regulation of Lab-Developed Tests – Roll Call

    Precision for Medicine’s Karen M. Becker, PhD, Managing Director, Translational and Regulatory Science, is quoted in an article regarding the upcoming Food and Drug Administration’s guidance on how it plans to oversee lab-developed tests used to diagnose conditions. Read the full article below:

  • News

    Q&A: Regulatory Expert Karen Becker Provides Context for Theranos, FDA Interactions – GenomeWeb

    Q&A: Regulatory Expert Karen Becker Provides Context for Theranos, FDA Interactions – GenomeWeb

    Karen M. Becker, PhD, Managing Director, Translational and Regulatory Sciences at Precision for Medicine, provides expertise for the diagnostics industry in navigating the complexities of the Food and Drug Administration.

  • News

    Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine

    Sandoz’ Filgrastim Biosimilar Is Now on the US Market – Pharmaceutical Commerce Magazine

    Precision for Medicine’s Larry Blandford quoted in an article from Pharmaceutical Commerce magazine on a new biosimilar product from Novartis’ Sandoz unit called Zarxio.

  • Thought Leadership

    Commentary: Big Data Analytics: The Next Evolution in Drug Development

    Commentary: Big Data Analytics: The Next Evolution in Drug Development

    Precision’s Deb Phippard, PhD, and Jared Kohler, PhD, address the potential of Big Data, analytics, and technology to increase efficiency and decrease costs in the drug development process in a guest column for Bioprocess Online. Read the full article here:

  • News

    Fewer Than Half Of Managed Care Execs Have Access to Health-Record Data They Value – Pharmaceutical Commerce

    Fewer Than Half Of Managed Care Execs Have Access to Health-Record Data They Value – Pharmaceutical Commerce

    Precision Advisors is cited in a Pharmaceutical Commerce article focusing on access to EHR data.

  • News

    Specialty Services for Life Sciences Clients – CEOCFO Magazine

    Specialty Services for Life Sciences Clients – CEOCFO Magazine

    Recently, Dan Renick, Co-President and Chief Commercial Officer, Precision for Medicine spoke with CEOCFO Magazine on the Future of Precision Medicine. Below is an excerpt from the article:

  • News

    Precision Acquires Precision Health Economics – PharmaVoice

    Precision Acquires Precision Health Economics – PharmaVoice

    Precision for Medicine’s acquisition of Precision Health Economics is covered in PharmaVoice.

     

  • News

    New Push Ties Cost of Drugs to How Well They Work – The Wall Street Journal

    New Push Ties Cost of Drugs to How Well They Work – The Wall Street Journal

    Precision for Medicine’s Larry Blandford quoted in today’s Wall Street Journal article: “New Push Ties Cost of Drugs to How Well They Work.” The effort is part of a growing push for so-called pay-for-performance deals amid complaints about the rising price of medications, some of which cost more than $100,000 per patient a year.

  • News

    Press Release: Precision for Medicine Acquires Precision Health Economics

    Press Release: Precision for Medicine Acquires Precision Health Economics

    Extends Leadership in Health Economics and Outcomes Research With a Focus on Evidence Generation in an Era of Precision Medicine

    Bethesda, MD, and Los Angeles, April 16, 2015 – Precision for Medicine (Precision), a specialized services company supporting next-generation approaches to drug development and commercialization, today announced the acquisition of Precision Health Economics (PHE). A world-renowned and cutting-edge health economics consultancy and analytics firm, PHE leverages the expertise of policy analysts, economists, clinicians, and academics to advance research on the most complex healthcare questions. Life sciences companies and policymakers worldwide turn to PHE to shape strategy, inform key healthcare decisions, and produce effective changes in policy through innovative research.

  • News

    Press Release: Precision for Medicine Launches the PATH™ Analytics Platform to Help Life Sciences Companies Accelerate Research

    Press Release: Precision for Medicine Launches the PATH™ Analytics Platform to Help Life Sciences Companies Accelerate Research

    BETHESDA, MD – March 26, 2015 – Precision for Medicine (www.precisionformedicine.com) today announced the PATH™ analytics platform, a unique tool that can identify, analyze, and provide novel scientific insights about important biomarkers, transforming traditional therapies into personalized therapeutics. PATH™ accelerates the research process, enabling a more streamlined framework for stratifying patient populations.

    The emergence of cost-efficient, high-throughput biomarker assays has brought big data-driven solutions to the forefront of healthcare. While scientific advancements have inspired the big data era of precision medicine, traditional analytics tools are not advancing at the same pace. As a result, the challenges facing R&D teams to advance precision medicine efforts have largely been unanswered – motivating Precision to develop PATH™ from the ground up to address the specific needs of precision medicine programs.

  • News

    Precision for Medicine Launches PATH to Help Stratify Patients for Personalized Medicine Studies – Genomeweb.com

    Precision for Medicine Launches PATH to Help Stratify Patients for Personalized Medicine Studies – Genomeweb.com

    Precision for Medicine has launched the PATH analytics platform, a new product for the translational research market that’s designed to help users combine and use clinical and genomic information to stratify patients as part of efforts to develop more tailored therapies.

  • Thought Leadership

    Better science begins by protecting your samples from draw to lab.

    Precision’s worldwide laboratory network ensures the integrity of your samples, from collection, through processing, preservation and analysis.

  • News

    Press Release: Precision for Medicine Awarded NIH Contract Valued at $28 Million

    Press Release: Precision for Medicine Awarded NIH Contract Valued at $28 Million

    (BETHESDA, MD) Nov. 4, 2014 – Precision for Medicine announced today that its subsidiary, Precision Bioservices, Inc., has been awarded a 7-year contract of up to $28 million to provide management and oversight of disease-study specimens for the National Institute of Allergy and Infectious Diseases (NIAID). NIAID is part of the National Institutes of Health (NIH), an agency of the US Department of Health and Human Services.

  • News

    Press Release: Precision for Medicine Acquires Hobart Group Holdings

    Press Release: Precision for Medicine Acquires Hobart Group Holdings

    (BETHESDA, MD) March 25, 2014 – Precision for Medicine, Inc., formed in 2012 to support next generation approaches to drug development and commercialization, announces the acquisition of Hobart Group Holdings, LLC (Hobart), a leading market access firm. With this addition, Precision for Medicine (Precision) has established the foundation for its next phase of growth in providing integrated solutions focused on demonstrating value in the era of precision medicine.

  • News

    Press Release: Precision for Medicine Appoints Karen Becker to Senior Leadership Team

    Press Release: Precision for Medicine Appoints Karen Becker to Senior Leadership Team

    Industry Expert in Regulatory Sciences and Commercial Strategy Joins New Service Organization Focused on Helping Life Science Companies Develop and Commercialize Next-Generation Medical Products

    (Bethesda, MD) April 8, 2013 – Precision for Medicine, Inc., (“Precision”) today announced that Karen Becker, PhD, has joined the company’s leadership team and will help life science companies capitalize on next-generation approaches to product development and commercialization.

    Dr. Becker has been named Managing Director. Prior to her appointment at Precision, Dr. Becker served as the CEO of Becker and Associates, a company she founded and built into one of the premier regulatory strategy firms for the biopharmaceutical and medical device industries.

  • News

    Press Release: Precision for Medicine Raises $150 Million to Fund Growth and Expansion

    Press Release: Precision for Medicine Raises $150 Million to Fund Growth and Expansion

    (Bethesda, MD) April 2, 2013 – Precision for Medicine, Inc., formed in 2012 to support next-generation approaches to drug development and commercialization, today announced that it has secured $150 million in private equity financing to support acquisitions and development. Precision for Medicine is building a comprehensive platform of specialized development and commercialization services to support life science companies that are seeking to capitalize on the benefits of patient-centered, precision medicine. Oak Investment Partners, J.H. Whitney and Company, and LCI Capital led the financing.

    Ethan D. Leder and Mark P. Clein, co-founders of the Maryland-based company, said the funding will be used to acquire the expertise and infrastructure necessary to guide innovative medical products from discovery to patients.

  • News

    Press Release: Precision for Medicine Expands Regulatory and Commercialization Teams to Support Next-Generation Medicines

    Press Release: Precision for Medicine Expands Regulatory and Commercialization Teams to Support Next-Generation Medicines

    Industry Experts Will Support the Development and Commercialization of Medical Diagnostic and Device Products, Including Companion Diagnostics for Next-Generation Medicines

    (Bethesda, MD) May 17, 2013 – Precision for Medicine, Inc., (“Precision”), the specialized scientific services company formed in 2012 to support next-generation medical products, today announced the appointment of 4 key executives, significantly increasing the breadth of its regulatory and commercialization services. The addition of these executives and their teams enhances Precision’s ability to support life science innovators as they address value, effectiveness, and patient access issues for next generation medicines.

  • Thought Leadership

    Acquire PBMG and PBMC subsets from our inventory of more than 100 donors.

    Precision provides PBMCs and highly purified subsets such as CD34+ cells, Monocytes, NK Cells, T-Cells and B-cells. Cells are extensively characterized and available immediately from our large inventory of more than 100 donors with different demographics and HLA types. To meet the precise needs of your research, custom isolations are offered from normal and disease state donors. We can isolate cells from whole blood or leukopaks and cryopreserve at the specified cell concentrations. For more details and to order specimens, visit buypbmcs.com

We're sorry, there are no results for "".

    Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.